Sun Pharma, Incyte settle dispute over LEQSELVI

As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S.

Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license. Other specific terms of the settlement and license agreement are confidential. 

Earlier, in April, Medical Dialogues team reported that the U.S. Court of Appeals for the Federal Circuit had vacated a preliminary injunction that had prevented the Indian drugmaker Sun Pharma from launching its autoimmune disorder treatment LEQSELVI (deuruxolitinib) in the United States.

LEQSELVI is a therapeutic treatment for an autoimmune condition that results in patchy hair loss, and its launch is expected to mark a significant milestone for Sun Pharma’s specialty drug portfolio in the U.S. market.

Read also: Court Removes Injunction on Sun Pharma's LEQSELVI Launch in US

Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents. 

Read also: Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC